These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 26782388

  • 1. Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma.
    Yvamoto EY, Ferreira RF, Nogueira V, Pinhe MA, Tenani GD, Andrade JG, Baitello ME, Gregório ML, Fucuta PS, Silva RF, Souza DR, Silva RC.
    Genet Mol Res; 2015 Dec 21; 14(4):17453-62. PubMed ID: 26782388
    [Abstract] [Full Text] [Related]

  • 2. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
    Helaly GF, Abou Shamaa LA.
    Egypt J Immunol; 2006 Dec 21; 13(1):27-38. PubMed ID: 17974148
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA, Gadelhak SA, El-Morsi DA, Abdelaziz MM, Abbas AT, El-Emshaty HM.
    Hepatogastroenterology; 2009 Dec 21; 56(94-95):1417-24. PubMed ID: 19950803
    [Abstract] [Full Text] [Related]

  • 4. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
    Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y.
    Anticancer Res; 2013 Mar 21; 33(3):1013-21. PubMed ID: 23482775
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Genetic variants associated with the progression of hepatocellular carcinoma in hepatitis C Egyptian patients.
    Motawi TK, Shaker OG, Ismail MF, Sayed NH.
    Gene; 2013 Sep 25; 527(2):516-20. PubMed ID: 23845776
    [Abstract] [Full Text] [Related]

  • 8. Association of genetic variants in the interleukin-18 gene promoter with risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus infection.
    Bakr NM, Awad A, A Moustafa E.
    IUBMB Life; 2018 Feb 25; 70(2):165-174. PubMed ID: 29341496
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of transforming growth factor alpha and vascular endothelial growth factor in diagnosis of hepatocellular carcinoma.
    El-Sherif WT, Makhlouf NA, El-Gendi SS, Hassan HI, Herdan OM.
    Egypt J Immunol; 2012 Feb 25; 19(2):53-65. PubMed ID: 23885407
    [Abstract] [Full Text] [Related]

  • 10. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
    Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC.
    Int J Cancer; 2004 Oct 20; 112(1):44-50. PubMed ID: 15305374
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Single nucleotide polymorphism in the promoter region of human alpha-fetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC).
    Chen GG, Ho RL, Wong J, Lee KF, Lai PB.
    Eur J Surg Oncol; 2007 Sep 20; 33(7):882-6. PubMed ID: 17433605
    [Abstract] [Full Text] [Related]

  • 13. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma.
    Ghosh A, Ghosh A, Datta S, Dasgupta D, Das S, Ray S, Gupta S, Datta S, Chowdhury A, Chatterjee R, Mohapatra SK, Banerjee S.
    Int J Cancer; 2016 Jun 01; 138(11):2732-44. PubMed ID: 26756996
    [Abstract] [Full Text] [Related]

  • 14. Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients.
    El-mezayen HA, Darwish H.
    Tumour Biol; 2014 Jul 01; 35(7):6501-9. PubMed ID: 24687551
    [Abstract] [Full Text] [Related]

  • 15. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.
    J Gastroenterol Hepatol; 2008 Oct 01; 23(10):1541-8. PubMed ID: 18422961
    [Abstract] [Full Text] [Related]

  • 16. Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-α, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma.
    Giacalone A, Montalto G, Giannitrapani L, Balasus D, Terranova A, Cervello M, Soresi M, Marasà L.
    OMICS; 2011 Mar 01; 15(3):193-6. PubMed ID: 21319995
    [Abstract] [Full Text] [Related]

  • 17. The role of vascular endothelial growth factor -634 G/C and its soluble receptor on chronic liver disease and hepatocellular carcinoma.
    Ratnasari N, Nurdjanah S, Sadewa AH, Hakimi M.
    Arab J Gastroenterol; 2016 Jun 01; 17(2):61-6. PubMed ID: 27426958
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and alpha-fetoprotein.
    Corradini SG, Morini S, Liguori F, Carotti S, Muda AO, Burza MA, Siciliano M, Molinaro A, Cantafora A, Blotta I, Merli M, Berloco P, Rossi M, Attili AF, Gaudio E.
    Liver Int; 2009 Jan 01; 29(1):103-12. PubMed ID: 18544126
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.